COVID-19 vaccine developed by UB startup approved for human trials

Published February 25, 2021

Print

Local news outlets including WKBW, WGRZ, The Lockport Journal and WIVB report that UB spinoff company POP Biotechnologies and biotech company EuBiologics have developed a COVID-19 vaccine candidate that has entered clinical trials in South Korea.

The vaccine, called EuCorVac-19, does not have to be stored at ultra-low temperatures and it targets specific parts of the virus.

“All the current vaccines are targeting the whole, what's called the spike protein. So the whole protein on the spike, so we're just targeting the very critical part of the spike protein,” Johnathan Lovell, co-founder of POP Biotechnologies and associate professor of biomedical engineering, told WKBW.

For its story, WGRZ also interviewed Raymond Cha, clinical associate professor in the School of Pharmacy and Pharmaceutical Sciences, about the challenges in the manufacturing of vaccines.

View the story on including WKBW, WGRZ, The Lockport Journal and WIVB.